進行食道癌患者におけるペムブロリズマブ（MK-3475）および／または化学療法の有無による併用療法の研究（MK-3475-06A）

基本情報

NCT ID

NCT05342636

ステータス

完了

試験のフェーズ

第1/第2相

試験タイプ

介入

目標被験者数

90

治験依頼者名

Merck Sharp & Dohme LLC

概要

This is a phase I/II multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of investigational agents with pembrolizumab, plus chemotherapy or lenvatinib, for the treatment of participants with advanced esophageal cancer who have failed 1 prior line of therapy and have not been previously exposed to programmed cell death 1 protein (PD-1)/ programmed cell death ligand 1 (PD-L1) based treatment. With protocol amendment 5 (effective: 17-November-2023), enrollment in study arms "Pembrolizumab plus MK-4830 plus Chemotherapy" and "Pembrolizumab plus MK-4830 plus lenvatinib" is discontinued.

対象疾患

介入

依頼者（Sponsor）

実施施設 (4)